Skip to main content
Close up of a hand using a tablet

Latest News

Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario

February 20, 2025

Apo-Teriparatide Injection ™ is a generic alternative to Forteo®.

Osteoporosis pharmacologic therapies are classified as antiresorptive therapy, which inhibits osteoclastic activity, and anabolic therapy, which stimulates new bone formation. Apo-Teriparatide is an anabolic therapy.

To view more information about provincial and territorial drug coverage visit https://osteoporosis.ca/provincial-territorial-drug-coverage/


OC MAKES THE NEWS – RECENT ITEMS

DENOZA® is now available in Canada

September 25, 2026

Latest News DENOZA® (denosumab injection), a biosimilar from Apotex, is now available in Canada September 25, 2026 PrDENOZA® is indicated for the treatment of postmenopausal osteoporosis, and to increase bone […]

Healthcare Professional Educational Events

August 19, 2026

Healthcare Professional Educational Events August 19, 2026 View the following information for two events for the healthcare professional: Canadian Symposia on Rare Bone Diseases 2026 ISCD Quality Bone Densitometry: for […]

Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones

July 7, 2026

Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]

© Osteoporosis Canada, 2026
Charitable Registration No. 89551 0931 RR 0001